Find Academic Supervisors

Martin PeiferView profile

Professor

• Computational Cancer Genomics
• Tumor Evolution
• Genome Instability
• +5 more

Professor Martin Peifer is a computational cancer genomics researcher at the University of Cologne, where he leads the Department of Translational Genomics. He serves as Principal Investigator of the Peifer Lab, which focuses on developing computational methods to analyze cancer genome sequencing data. His work is deeply integrated with the Center for Data and Simulation Science and he is an active member of the International Cancer Genome Consortium and the Pan-Cancer Analysis of Whole Genomes project. Peifer's research interests center on computational approaches to understanding cancer biology, with particular emphasis on tumor evolution and genome instability mechanisms. His lab develops methods to analyze somatic genome alterations including point mutations, copy number changes, and rearrangements. They also create computational tools for integrative genome analyses, tumor evolution reconstruction, and single-cell sequencing data analysis (both RNA and DNA). His interdisciplinary team applies high-performance computing and machine learning to interpret complex cancer sequencing data, aiming to better understand tumorigenesis, clonal evolution, and therapy resistance. Analysis of Peifer's extensive publication record reveals a strong focus on neuroblastoma and lung cancer genomics, with particular attention to tumor evolution patterns and genomic instability mechanisms. His work spans multiple cancer types but maintains consistent themes of computational methodology development and application to understand cancer progression and treatment resistance. The publications demonstrate increasing sophistication in analyzing intra-tumor heterogeneity and clonal dynamics over time. Peifer leads an active research group including postdoctoral fellows (Joel Kaufmann, Dr. Stephanie Pabel, Agnieszka Rumińska) and PhD students (Magdalena Seiffert, Justinas Valiulis). His lab is involved in the Collaborative Research Center 1399 focused on Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer, indicating significant grant funding and collaborative research efforts. The Peifer Lab operates at the intersection of computational biology and cancer research, maintaining an interdisciplinary approach that combines bioinformatics, machine learning, and high-performance computing to address complex questions in cancer genomics. Their work has significant implications for understanding cancer evolution and developing more effective treatment strategies.

• Neuro-oncology
• Neuropathology
• Glioblastoma
• +3 more

Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis

• Transposable elements
• Somatic mutations
• Cancer genomics
• +7 more

Eunjung (Alice) Lee, PhD is an Associate Professor in the Division of Genetics and Genomics at Boston Children's Hospital and Harvard Medical School. She serves as a member of the Global Faculty at the University of Cologne, specifically affiliated with their Core Profile Area on Aging-Associated Diseases and the CECAD Cluster of Excellence focused on cellular stress responses in aging-associated diseases. Dr. Lee received her PhD in Bioinformatics from the Korea Advanced Institute of Science and Technology (KAIST), conducting research in integrative systems biology with Trey Ideker at the University of California, San Diego. She completed her postdoctoral training with Peter J. Park at Harvard Medical School. Her educational background combines computational expertise with biological applications, establishing her unique position at the intersection of bioinformatics and disease mechanisms. Dr. Lee's research program centers on elucidating the role of transposable elements and somatic mutations in human pathologies including cancer, aging processes, and neurodegenerative conditions. Her laboratory has pioneered computational methods for analyzing cancer whole genome and single-neuron genome sequencing data, making landmark discoveries about somatic retrotransposition in human cancers and the brain. Her team has demonstrated how transposons influence disease through multiple mechanisms including shaping cancer immunity, generating novel molecules via alternative splicing in human tissues and cancers, and contributing to rare diseases through RNA splicing alterations. Currently, her research focuses on developing intervention strategies targeting these mechanisms and investigating somatic mutation patterns in neurodegenerative conditions using cutting-edge single-cell genomic technologies. Analysis of Dr. Lee's publication record reveals a strategic progression from foundational discoveries about somatic retrotransposition in cancers to increasingly sophisticated investigations of genomic mosaicism across diverse disease contexts. Her work consistently bridges computational innovation with biological insight, with recent publications emphasizing single-cell resolution of somatic mutations in neurodegeneration and DNA repair disorders. The research demonstrates growing methodological sophistication and clinical relevance, particularly in connecting genomic instability mechanisms to potential therapeutic approaches. NIH New Innovator Award (DP2) recognizing high-impact, early-stage investigation Leadership of transposon analysis working group in the SMaHT (Somatic Mosaicism Across Human Tissue) Network, an NIH consortium Co-organizer of the inaugural Keystone meeting on somatic mosaicism (2025) Regularly invited speaker at major international conferences on transposons, genomics, and genetics Dr. Lee leads an active research program developing and applying computational genomics methods to investigate somatic genomic variation. Her laboratory maintains strong connections with the broader scientific community through leadership roles in national consortia and conference organization. She is actively shaping the emerging field of somatic mosaicism research, with particular emphasis on translating basic genomic discoveries into potential clinical applications for cancer and neurodegenerative diseases. Her work bridges multiple disciplines including computational biology, cancer genomics, neuroscience, and aging research.

Phil H JonesView profile

Professor

• Cancer Biology
• Stem Cell Research
• Somatic Mutations
• +5 more

Phil H Jones is a Senior Group Leader at the Wellcome Sanger Institute and Programme Leader at the MRC Cancer Unit, University of Cambridge. He leads the Jones Group which focuses on understanding how cancer-associated DNA changes in normal stem cells alter their behavior, allowing them to spread through normal tissues—the critical first step toward cancer development. Institution: MRC Cancer Unit, University of Cambridge Research Program: Cancer, Ageing and Somatic Mutation Programme Professional Recognition: Fellow of the Royal Society, Fellow of the Academy of Medical Sciences Dr. Jones's research centers on how mutations that alter the competitive fitness of normal stem cells give mutant stem cells the ability to spread through normal tissues. His current work employs deep sequencing, advanced imaging, gene editing, and single-cell analysis to define how oncogenic mutations alter stem cell behavior during aging and the earliest stages of cancer development in skin and esophagus. His lab-based studies complement his clinical work at Addenbrooke's Hospital, where he treats patients with non-melanoma skin cancer. Analysis of his recent publications reveals a consistent focus on somatic mutations in normal epithelial tissues, particularly examining how specific mutations (such as those in p53, Notch1, and PIK3CA) confer competitive advantages to cells, enabling clonal expansion. His work demonstrates that normal tissues become extensively colonized by mutant cells with age, with some mutations increasing cancer risk while others may actually decrease it. A key finding across multiple publications is that mutant clones can outcompete and eliminate early-stage tumors, suggesting novel approaches to cancer prevention. Fellow of the Royal Society Fellow of the Academy of Medical Sciences Multiple high-impact publications in Nature, Science, and Cell journals Dr. Jones collaborates extensively with Cancer Research UK, the Department of Oncology at the University of Cambridge, and the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. His research is highly translational, aiming to apply fundamental discoveries about somatic evolution in normal tissues to develop rational interventions that reduce cancer risk in high-risk patients. The Jones Group employs a multidisciplinary approach combining experimental biology with computational modeling to understand the evolutionary dynamics of mutant clones in aging tissues. The Jones Group operates within the Cancer, Ageing and Somatic Mutation Programme at the Wellcome Sanger Institute, utilizing advanced 3D culture methods, gene editing, live imaging, and single-cell analysis capabilities. Their research infrastructure supports studies of both skin epidermis and esophageal epithelium, with particular focus on how lifestyle factors (sun exposure, alcohol consumption) and aging influence the somatic mutation landscape of normal tissues.

Claude BeckerView profile

Professor

• Plant Epigenetics
• Plant-Microbe Interactions
• Allelopathy
• +3 more

Prof. Dr. Claude Becker is a faculty member at the Faculty of Biology, Ludwig Maximilian University of Munich , specializing in plant genetics and epigenetics. His research focuses on biochemical interactions in plant communities and the role of epigenetic marks in environmental adaptation. Specializations: Epigenetic regulation, allelopathy, plant-microbe interactions, DNA methylation dynamics Key Projects: Studying heritable phenotypic variation in clonal plants, analyzing stress-responsive epigenetic hotspots, and investigating gene cluster evolution in Oryza species. Recent publications highlight his work on transposable element dynamics, microbiome feedback mechanisms, and metabolic specialization in plant interactions. His research combines molecular biology with ecological perspectives to understand plant adaptation strategies. Contact: claude.becker@biologie.uni-muenchen.de

Korbinian SchneebergerView profile

Professor

• Computational Genetics
• Genome Plasticity
• Plant Genomics
• +6 more

Prof. Korbinian Schneeberger is a full Professor of Computational Genetics and Genome Plasticity at the Ludwig Maximilian University of Munich , embedded within the Graduate School of Life Science Munich (LSM) . He leads a multidisciplinary team of bioinformaticians, biologists, and biotechnologists, all driven by a shared curiosity in genomic technologies and plant genome evolution. Contact: k.schneeberger@lmu.de . Research Focus: Genome plasticity and mutational dynamics across plant species Development and refinement of next-generation sequencing and assembly pipelines Comparative genomics, pan-genome construction, and structural variation Epigenetic regulation and transposon biology in plant genomes Meiotic recombination and crossover patterning in holocentric plants Application of single-cell and single-nucleus technologies to dissect gamete-level variation His laboratory develops widely-used bioinformatics tools—including SHOREmap , findGSE , SyRI , and plotsr —that enable the community to assemble, compare, and interpret plant genomes at unprecedented resolution. Recent work advances understanding of centromere evolution, adaptation to extreme soils, layer-specific somatic mutation patterns in fruit trees, and large-scale Arabidopsis population genomics. Scientific Output & Impact: Since 2015, Prof. Schneeberger has published more than 60 peer-reviewed articles, many appearing in top-tier journals such as Nature Genetics , Nature Plants , and Genome Biology . His 2025 studies already tackle the mutational landscape of Arabidopsis centromeres, scalable eQTL mapping in gametes, and the phased pan-genome of tetraploid potato, underscoring a trajectory at the forefront of plant genomic science. Funding & Collaborations: Research in the Schneeberger Lab is supported by multiple national and international grants, providing resources for high-throughput sequencing, computational infrastructure, and interdisciplinary training. The group actively collaborates with leading plant research centers worldwide, sharing data and tools to accelerate discoveries in crop improvement and evolutionary biology. Team & Environment: The lab operates as a vibrant, international environment with state-of-the-art wet-lab and computational facilities. Trainees and staff benefit from the rich ecosystem of LSM, including structured doctoral programs, career mentoring, and access to cutting-edge core facilities.

Raheleh RahbariView profile

Research Fellow

• Cancer genetics
• Ageing
• Germline mutations
• +5 more

Dr. Raheleh Rahbari is a Cancer Research UK Career Development Fellow and Group Leader at the Wellcome Sanger Institute, where she leads the Rahbari Group within the Cancer, Ageing and Somatic Mutation Programme. Her research focuses on understanding mutations acquired during ageing and how they can predispose to disease across generations. Dr. Rahbari's research interests span several key areas: Studying variation in germline mutation rates across families Investigating mutational processes operative in the germline Examining the impact of germline genetic mosaicism in offspring Using somatic mutations to infer the clonal dynamics of germline tissues Understanding how mutations acquired during ageing contribute to cancer predisposition Her recent publications demonstrate a strong focus on mutational landscapes in both somatic and germline cells, with particular emphasis on how these mutations relate to cancer development and predisposition. Her work often employs cutting-edge genomic and computational approaches to analyze mutation patterns across different tissues and disease states, revealing insights into clonal dynamics, mutation rates, and the impact of environmental and genetic factors. Dr. Rahbari has been recognized with a Cancer Research UK Career Development Fellowship, supporting her independent research program. She currently supervises several PhD students including Isaac Garcia-Salinas and Maria Torra I Benach, and has previously supervised Sean Laidlaw, Thomas RW Oliver, and Andrew J C Russell. Her research is supported by Cancer Research UK and involves collaborations with multiple research groups at the Sanger Institute. Dr. Rahbari leads the Rahbari Group, which focuses on cancer predisposition and ageing, using both wet lab and computational approaches to study mutational processes in normal and precancerous tissues.

Johannes FrankView profile

Associate Professor

• Plant Epigenomics
• Bioinformatics
• Statistical Genetics
• +3 more

Prof. Johannes Frank is an Associate Professor at the Technical University of Munich (TUM), leading the Plant Epigenomics lab (JLAB) within the TUM School of Life Sciences. His research focuses on understanding chromatin-based mechanisms of genome regulation and epigenetic inheritance in plants. He investigates how epigenetic variation arises, stabilizes across generations, and influences agriculturally and evolutionarily relevant traits, with a long-term goal of applying this knowledge to improve crops. Frank received his PhD from Pennsylvania State University in statistical genetics and held postdoctoral positions at CNRS (France) and the University of Groningen (Netherlands). He joined TUM as the Rudolf Mössbauer Professor at the TUM Institute for Advanced Study (TUM-IAS) and was promoted to Associate Professor in 2022. His work combines bioinformatics with high-throughput molecular data to study epigenetic dynamics in plant populations, including long-lived species like trees. Key research areas include the molecular properties of epimutation hotspots, somatic mutation rates in perennial plants, and the role of epigenetic variation in stress adaptation. His lab explores tools like deep learning for predicting 3D chromatin interactions and integrates genomic/epigenomic data to infer population histories. Recent findings highlight the impact of growth rates and environmental stress on epigenetic stability. Frank collaborates globally, contributing to projects like the *Populus trichocarpa* genome assembly and the identification of genetic modifiers of epimutation rates. His work bridges fundamental epigenetic mechanisms with applied agricultural and ecological outcomes, emphasizing the role of epigenetics in plant adaptation and resilience.

• Oncology
• Neuro-oncology
• Medulloblastoma
• +3 more

B. Wainwright is a researcher at the German Cancer Research Center (DKFZ) specializing in medulloblastoma and Sonic Hedgehog pathway research within the Department of Molecular Oncology. With publications spanning from 2014 to 2025, Wainwright has established themselves as a consistent contributor to the field of neuro-oncology. Research interests focus on molecular mechanisms of medulloblastoma development, with particular emphasis on the Sonic Hedgehog signaling pathway, germline mutations in cancer predisposition, and identification of therapeutic targets. Key areas include tumor cell survival mechanisms, medulloblastoma subtypes, and the role of specific proteins like Netrin-1 and Neogenin1 in cancer progression. Recent publications demonstrate a trajectory from fundamental molecular research toward translational applications, with involvement in studies examining potential therapeutic targets like MDM2 and clinical applications of pathway inhibitors. The research shows strong international collaboration patterns across multiple institutions. While specific awards and mentoring activities aren't documented in the provided materials, the consistent publication record in high-impact journals (Nature, Cancer Cell, Nature Communications) indicates recognition within the neuro-oncology research community. Current work appears focused on developing targeted therapies for medulloblastoma subtypes with particular genetic profiles.

• Pediatric Oncology
• Neuro-Oncology
• Cancer Research
• +7 more

Professor Stefan M. Pfister serves as Director of Preclinical Pediatric Oncology at the Hopp Children's Tumor Center (KiTZ) Heidelberg and Head of the Department of Pediatric Neuro-Oncology at the German Cancer Research Center (DKFZ). He is also a Senior Physician at the Department of Pediatrics III, Oncology, Hematology, Immunology and Pulmonology at Heidelberg University Hospital, where he serves as Deputy Head of the Section "Center for Individualized Pediatric Oncology (ZIPO) and Brain Tumors". His research focuses on pediatric neuro-oncology, particularly molecular genetics of childhood brain tumors. He leads the research group "Molecular Genetics of Childhood Brain Tumors" at DKFZ and Heidelberg University Hospital. His work prominently features DNA methylation-based tumor classification, medulloblastoma genomics, and translational research in pediatric brain cancers. His extensive publication record shows significant contributions to the 2021 WHO Classification of Central Nervous System Tumors, DNA methylation profiling for tumor classification, and comprehensive genomic analyses of childhood cancers. His research bridges molecular diagnostics with clinical applications, aiming to improve classification systems and treatment approaches for pediatric brain tumors. Director of Preclinical Pediatric Oncology, Hopp Children's Tumor Center Heidelberg Head of Department of Pediatric Neuro-Oncology, German Cancer Research Center (DKFZ) Senior Physician, Department of Pediatrics III, Heidelberg University Hospital Deputy Head, Center for Individualized Pediatric Oncology (ZIPO) and Brain Tumors Director of Children's Tumor Center (KiTZ) Heidelberg since 2016 Professor Pfister has received recognition through his extensive publication record in top-tier journals including Nature, Nature Genetics, and Neuro-Oncology. His leadership in international consortia has advanced the field of pediatric neuro-oncology through collaborative research efforts spanning multiple continents. His academic journey began with medical studies at Hamburg and Tübingen universities (1994-2002), followed by postdoctoral work at Dana-Farber Cancer Institute and DKFZ. He completed his habilitation and Venia Legendi for pediatrics at Heidelberg University in 2010 and has led his research group since 2006. His additional Master's degree in Management (2015) complements his scientific leadership roles.

Anja NagelView profile

Adjunct Professor

• Molecular Biology
• Genetics
• Stem Cell Research
• +7 more

Anja Nagel is an Adjunct Professor in the Department of Genetics at the University of Hohenheim, where she leads research on molecular mechanisms of stem cell resilience. Her work focuses on genome integrity, cellular differentiation, growth regulation, and immunity using Drosophila as a model organism. She applies advanced molecular techniques including CRISPR/Cas9 genome engineering to investigate fundamental biological processes with potential therapeutic applications, particularly in leukemia research. Dr. Nagel's primary research interests center on three interconnected areas: the role of the putzig gene in growth regulation and epigenetic control of genome stability in germ line stem cells; DNA repair mechanisms in Drosophila with relevance to human diseases like cancer; and the Notch signaling pathway's role in hematopoiesis and immune cell differentiation. Her laboratory has made significant contributions to understanding how post-translational modifications, particularly phosphorylation, regulate Notch signaling activity through the CSL/Su(H) transcription factor. Analysis of her recent publications reveals a consistent focus on Notch signaling pathway mechanisms, with increasing emphasis on the intersection between immune response and developmental processes. Her work demonstrates how Drosophila genetics can illuminate conserved molecular pathways relevant to human health, particularly in blood cell development and cancer biology. The research employs sophisticated genetic approaches including CRISPR/Cas9 genome editing, phospho-specific mutations, and detailed phenotypic analyses. Dr. Nagel's research is supported by the German Research Foundation (DFG), with current projects specifically funded under grants NA 427/6-1 (focusing on putzig and genome stability) and NA 427/5-1 (investigating Notch signaling in hematopoiesis). Her laboratory maintains an active research program with consistent publication output spanning from fundamental genetic discoveries to potential therapeutic applications.

Sam BehjatiView profile

Clinical Professor

• Cancer Genomics
• Single Cell Transcriptomics
• Childhood Cancer
• +5 more

Sam Behjati is a Clinical Professor of Paediatric Oncology at the University of Cambridge and a Group Leader & Wellcome Senior Research Fellow at the Wellcome Sanger Institute. He serves as an Honorary Consultant Paediatric Oncologist at Addenbrooke's Hospital and leads research at the intersection of Cellular Genetics and Cancer programs. His work focuses on understanding the developmental origins of childhood cancers through innovative genomic approaches. Dr. Behjati's research interests center on unraveling the identity and origin of cancer cells, with particular emphasis on childhood cancers. His team combines cutting-edge single cell transcriptomics with cancer genomics to understand normal human development and how developmental processes relate to disease. They investigate the precise cellular origins of tumors, matching transcriptomic profiles of diseased cells with normal tissues, and identifying clinically relevant features of disease transcriptomes. This work has significant implications for understanding the developmental nature of childhood cancers and improving diagnostic and therapeutic approaches. Analysis of Dr. Behjati's recent publications reveals a strong focus on childhood cancers, particularly Wilms tumor, with extensive work on single-cell transcriptomics, somatic mutation analysis, and developmental origins of cancer. His research spans multiple disciplines including cancer genomics, developmental biology, and pediatric oncology, with consistent contributions to understanding the molecular basis of childhood tumors. Royal Society Crick Medal and Lecture Foulkes Foundation Academy of Medical Sciences Medal Pezcoller Foundation-EACR Rising Star Award EMBO Young Investigator Liddy Shriver Early Research Award | Connective Tissue Oncology Society Dr Simon Newell Early Career Investigator of the Year (Sparks) award Science & SciLifeLab Prize for Young Scientists Wellcome Intermediate Clinical Fellowship Robert J. Arceci Innovation Award | St. Baldrick's Foundation Donald Paterson Prize | Royal College of Paediatrics and Child Health Dr. Behjati leads the Behjati Group at the Wellcome Sanger Institute, which is part of both the Cellular Genomics and Cancer, Ageing and Somatic Mutation programmes. His team applies single-cell techniques to understand normal human development and its relationship to disease, with a particular focus on childhood cancers. The group collaborates extensively with external partners including Wellcome, St Baldrick's Foundation, and the Little Princess Trust, and contributes to major initiatives like the Human Cell Atlas.

Inigo MartincorenaView profile

Researcher

• Somatic Mutation
• Cancer Genomics
• Ageing Research
• +3 more

Inigo Martincorena is a Group Leader at the Wellcome Trust Sanger Institute, where he leads the Martincorena Group focused on somatic evolution research within the Cancer, Ageing and Somatic Mutation Programme. His career path includes positions as a CRUK Career Development Fellow, Research Fellow at Queens' College, University of Cambridge, and Postdoctoral Fellow at the Sanger Institute, demonstrating his deep integration within the academic research community. Dr. Martincorena's research centers on understanding somatic mutation and evolution in normal tissues and its implications for cancer development and ageing. His groundbreaking work has revealed that human tissues are mosaics of thousands of competing clones carrying cancer-driver mutations, fundamentally changing our understanding of early cancer development. His group has published seminal studies on somatic mutation landscapes in normal skin, esophagus, bladder, and other tissues, showing that these processes are widespread across human tissues. The Martincorena Group combines genome sequencing, laser capture microscopy, and computational data analysis to investigate somatic mutation dynamics, with current work focusing on characterizing somatic mutation in healthy tissues, exploring the role of somatic mutation in ageing and disease, studying somatic mutation in other species, and developing new experimental and computational methods. Among his notable scientific achievements, Dr. Martincorena holds the prestigious CRUK Career Development Fellowship and has developed dNdScv, an evolutionary method to study selection in cancer and somatic evolution that has become widely used in the field. His research has been published in top-tier journals including Nature, Science, and Cell, with multiple highly cited papers that have reshaped understanding of somatic evolution in normal tissues. Dr. Martincorena leads a research group within the Cancer, Ageing and Somatic Mutation Programme at the Sanger Institute, collaborating with numerous researchers and institutions worldwide. His group's work has significant implications for understanding cancer development, improving early detection methods, and potentially developing new approaches to prevent cancer. The Martincorena Group continues to push the boundaries of somatic mutation research with innovative methodologies and comprehensive analyses of normal tissue genomics.

Jyoti NangaliaView profile

Professor

• Blood Cancer Genetics
• Somatic Mutation Patterns
• Methylation Changes
• +7 more

Dr. Jyoti Nangalia is a distinguished Group Leader in the Cancer, Ageing and Somatic Mutation Programme at the Wellcome Sanger Institute and a Principal Investigator at the Wellcome-MRC Cambridge Stem Cell Institute. She also serves as an Honorary Consultant Haematologist at Cambridge University Hospitals NHS Foundation Trust, where she treats patients with chronic myeloid malignancies. Dr. Nangalia received her medical education at the University of Cambridge (St John's College), earning a BA with First Class Honors followed by an MB BChir medical degree. She completed her PhD at the University of Cambridge and Sanger Institute, where she discovered CALR mutations in myeloproliferative neoplasms. Her research focuses on understanding somatic mutation patterns, methylation changes, and clonal selection throughout life and how these processes alter during ageing and cancer development. Her group employs innovative approaches including single-cell derived whole genome sequencing, phylogenetic analysis, mathematical modeling, and population simulations to study clonal trajectories to blood cancers and methylation dynamics across tissues and lifespan. Her earlier groundbreaking work identified CALR mutations in patients with JAK2-unmutated myeloproliferative neoplasms, which is now routinely tested in clinical practice and included in international WHO guidelines. Analysis of Dr. Nangalia's recent publications reveals a strong focus on clonal dynamics in hematopoiesis across the human lifespan, with particular emphasis on blood cancer trajectories, methylation changes during ageing, and the development of personalized cancer prediction models. Her work integrates large-scale genomic data with clinical parameters to improve early detection and intervention strategies for blood cancers. Johnstone & Florence Stoney Scholarship from the British Federation of Women Graduates Cancer Research UK Clinician Scientist Fellow (2017) Cancer Research UK Advanced Clinician Scientist Fellow Dr. Nangalia leads the Nangalia Group at the Sanger Institute, which includes staff scientists, postdoctoral fellows, and PhD students. Her research is supported by Cancer Research UK and other major funding bodies. She is actively involved in clinical research, leading molecular analysis for clinical trials of myeloproliferative neoplasms and contributing to national guidelines for these conditions. Her group has developed predictive tools for blood cancer prognosis that integrate clinical and genomic parameters. The Nangalia Group maintains strong collaborations with clinical teams at Cambridge University Hospitals and participates in international research networks focused on blood cancers and clonal evolution. Their work bridges basic science and clinical application, with the goal of translating genomic discoveries into improved patient outcomes.

• Hair follicle development
• Regeneration
• Dermal niche
• +7 more

Peggy Myung, MD, PhD is Vice Chair of Research and Associate Professor of Dermatology and Pathology at Yale School of Medicine. She maintains strong affiliations across multiple Yale entities including the Yale Cancer Center, Yale Stem Cell Center, Cancer Signaling Networks Program, and Pathology Research Program in Translational Biomedicine. Dr. Myung leads the Myung Lab which focuses on hair follicle development and regeneration research, with applications to understanding skin cancer mechanisms. Dr. Myung received her MD and PhD from the University of Pennsylvania in 2003, completed residencies at Hospital of the University of Pennsylvania and University Hospitals Case Medical Center, and a fellowship at Yale University School of Medicine in 2014. She is board certified in both Dermatology (2012) and Dermatopathology (2014, with recertification in 2025). Her research program investigates how heterotypic signals between the skin epidermis and dermis regulate robust and organized hair follicle growth during embryonic development and adult regeneration. The Myung Lab specifically examines: (1) how cellular behaviors such as cell divisions and movement are regulated by key morphogenetic signals during regeneration, (2) how these signals are spatially disseminated to ensure robust but patterned growth, and (3) how these mechanisms contribute to disorganized growth during tumorigenesis. The hair follicle serves as an ideal model for these studies due to its accessibility and well-characterized cyclical regeneration dependent on resident stem cells. Dr. Myung's recent publication record demonstrates consistent productivity in high-impact journals, with a growing emphasis on single-cell genomic techniques and computational approaches to understand cellular interactions at unprecedented resolution. Her work bridges developmental biology, dermatology, and cancer research, with particular focus on Wnt/β-catenin signaling and epithelial-mmesenchymal interactions. Dr. Myung has received notable recognition including: $30K Biotech Accelerator Award (June 2023) Yale Medicine 'Top Doctor' listing (2024) As Vice Chair of Research, Dr. Myung oversees research initiatives within the Department of Dermatology while maintaining an active laboratory program that combines multi-photon imaging, quantitative RNA fluorescent in situ hybridization, single-cell RNA/ATAC sequencing, and in vivo mouse genetic models. Her long-term goal is to develop novel treatments for hair loss and to prevent and treat non-melanoma skin cancer by applying knowledge of hair morphogenetic signals to suppress aberrant growth in carcinogenesis.